Eli Lilly and Company

NYSE:LLY

Drug Manufacturers - General

Healthcare
$1,382.54 -0.95%

-$10.54 today

Market cap
$1.30T
Beta
0.52
P/E (TTM)
39.0
EPS (TTM)
$28.26
Dividend yield
0.59%
52W Low $623.78High $1,182.73

Volume 2.58M

Average 3.19M

LLY Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Eli Lilly and CompanyNYSE: LLY

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables outflow grows to $0

Q2 FY2026 accounts payables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts payables was $0. Over 3 fiscal years it compounded at +97.0% a year.

Context

  • Accounts payables amounted to 15.6% of revenue in FY2025, up 9.8 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$10.19B+290.5% YoY
LTMJun 2026
$0— YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+290.5%——
3-year CAGR+97.0%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
10.19B USD
Year-over-year change
+290.5%

Accounts Payables vs competitors

How LLY compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Accounts payables amounts to 0.0% of revenue for LLY, versus a peer median of 0.3%.
LLY Competitors
Accounts Payables for LLY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$2.72B USD+14189.5%+29.4%2.7%
ABBVAbbVie Inc.LTM Jun 2026$740M USD-44.5%-16.0%1.1%
SNYSanofiLTM Jun 2026€396.61M EUR—+9.7%0.8%
NVSNovartis AGLTM Jun 2026$194.29M USD-248.3%+14.9%0.3%
AMGNAmgen Inc.LTM Jun 2026$157M USD-121.4%+40.6%0.4%
LLYEli Lilly and CompanyLTM Jun 2026$0 USD—+97.0%0.0%
MRKMerck & Co., Inc.LTM Jun 2026$0 USD——0.0%
AZNAstraZeneca PLCLTM Sep 2026$0 USD——0.0%
NVONovo Nordisk A/SLTM Jun 2026DKK 0 DKK——0.0%
PFEPfizer Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding LLY) —-83.0%+14.9%0.3%

Competitors are the stored peer set for LLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income5.58B6.24B5.24B10.59B20.64B
Depreciation & Amortization1.55B1.52B1.53B1.77B2B
Deferred Income Tax(802.3M)(2.19B)(2.34B)(2.68B)(1.71B)
Stock-Based Compensation342.8M371.1M628.5M645.6M626M
Change in Working Capital(1.01B)(800K)(3.06B)(5.39B)(8.09B)
Accounts Receivables(1.28B)(299.6M)(2.45B)(2.16B)(7B)
Inventory(235.9M)(599.7M)(1.43B)(2.51B)(4.67B)
Accounts Payables(1.01B)1.33B4.27B2.61B10.19B
Other Working Capital1.52B(433.2M)(3.45B)(3.33B)(6.61B)
Other Non-Cash Items1.71B1.63B2.24B3.88B3.35B
Operating Cash Flow7.37B7.59B4.24B8.82B16.81B
Capital Expenditures(1.98B)(2.99B)(7.39B)(5.06B)(7.84B)
Acquisitions (Net)(747.4M)(327.2M)(1.04B)(947.7M)(661M)
Purchases of Investments(1.01B)(707.6M)(829M)(775.8M)(645M)
Sales of Investments847.4M463.6M700.3M522.5M964M
Other Investing Activities(644.3M)(1.34B)(2.53B)303.1M(2.79B)
Investing Cash Flow(2.87B)(3.76B)(7.15B)(9.3B)(10.97B)
Debt Repayment501.4M(62M)8.65B8.9B8.05B
Common Stock Issued00000
Common Stock Repurchased(1.25B)(1.5B)(750M)(2.5B)(4.11B)
Dividends Paid(3.09B)(3.54B)(4.07B)(4.68B)(5.38B)
Other Financing Activities(295.9M)(308.9M)(335M)(490.6M)(772M)
Financing Cash Flow(4.13B)(5.41B)3.5B1.23B(2.21B)
Effect of Forex Changes(205.7M)(167.6M)168.6M(296.7M)372M
Net Change in Cash161.4M(1.75B)751.6M449.8M4B
Free Cash Flow5.39B4.6B(3.15B)3.76B8.97B

Eli Lilly and Company

NYSE:LLY

Intrinsic Alpha fair value

Locked

Current Price

$1,382.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.